Therapeutic Significance of Elevated Tissue Transglutaminase Expression in Pancreatic Cancer

Purpose: Tissue transglutaminase (TG2) is a multifunctional protein that is implicated in development of drug resistance and metastasis. Therefore, we examined therapeutic targeting of TG2 for inhibiting growth and metastasis of in vivo growing pancreatic ductal adenocarcinoma (PDAC) in nude mice. Experimental Design: We implanted Panc-28 pancreatic cancer cells to induce orthotopic PDAC tumors in nude mice and determined the efficacy of liposomal TG2 small interfering RNA (siRNA) either alone or in combination with gemcitabine. Results: We show that down-regulation of endogenous TG2 by siRNA could effectively block the growth of PDAC. Moreover, down-regulation of TG2 significantly enhanced the therapeutic efficacy of gemcitabine against PDAC and inhibited metastatic spread of the disease. The antitumor activity was related to inhibition of proliferation, angiogenesis, and Akt phosphorylation. Conclusion: siRNA-mediated down-regulation of TG2 represents a promising therapeutic approach for improved treatment of PDAC.

[1]  Huamin Wang,et al.  Tissue Transglutaminase Regulates Focal Adhesion Kinase/AKT Activation by Modulating PTEN Expression in Pancreatic Cancer Cells , 2008, Clinical Cancer Research.

[2]  A. Verma,et al.  Transglutaminase-mediated activation of nuclear transcription factor-kappaB in cancer cells: a new therapeutic opportunity. , 2007, Current cancer drug targets.

[3]  D. Matei,et al.  Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. , 2007, Cancer research.

[4]  A. Verma,et al.  Tissue transglutaminase-mediated chemoresistance in cancer cells. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[5]  B. Aggarwal,et al.  Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products. , 2007, Cancer research.

[6]  Amit Verma,et al.  Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells , 2007, Oncogene.

[7]  Y. Kondo,et al.  Tissue Transglutaminase Inhibits Autophagy in Pancreatic Cancer Cells , 2007, Molecular Cancer Research.

[8]  Soo-Youl Kim,et al.  Reversal of Drug Resistance in Breast Cancer Cells by Transglutaminase 2 Inhibition and Nuclear Factor-KB Inactivation , 2006 .

[9]  Huamin Wang,et al.  Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. , 2006, Cancer research.

[10]  B. Aggarwal,et al.  Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. , 2006, Cancer research.

[11]  Liz Y. Han,et al.  Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy , 2006, Clinical Cancer Research.

[12]  Suhendan Ekmekcioglu,et al.  Implications of tissue transglutaminase expression in malignant melanoma , 2006, Molecular Cancer Therapeutics.

[13]  K. Mehta,et al.  Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells , 2006, Oncogene.

[14]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[15]  J. Pan,et al.  Retinoic acid receptors and tissue-transglutaminase mediate short-term effect of retinoic acid on migration and invasion of neuroblastoma SH-SY5Y cells , 2006, Oncogene.

[16]  K. Mehta.  Mammalian transglutaminases: a family portrait. , 2005, Progress in experimental tumor research.

[17]  A. Moser,et al.  Current management of locally advanced pancreatic cancer , 2005, Nature Clinical Practice Gastroenterology &Hepatology.

[18]  Anil K Sood,et al.  Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. , 2005, Cancer research.

[19]  A. Sahin,et al.  Prognostic Significance of Tissue Transglutaminase in Drug Resistant and Metastatic Breast Cancer , 2004, Clinical Cancer Research.

[20]  R. Cerione,et al.  Augmentation of Tissue Transglutaminase Expression and Activation by Epidermal Growth Factor Inhibit Doxorubicin-induced Apoptosis in Human Breast Cancer Cells* , 2004, Journal of Biological Chemistry.

[21]  Suresh Mishra,et al.  Tissue Transglutaminase Has Intrinsic Kinase Activity , 2004, Journal of Biological Chemistry.

[22]  S. Priglinger,et al.  TGF-beta2-induced cell surface tissue transglutaminase increases adhesion and migration of RPE cells on fibronectin through the gelatin-binding domain. , 2004, Investigative ophthalmology & visual science.

[23]  Christine A Iacobuzio-Donahue,et al.  Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. , 2003, Cancer research.

[24]  Devanand M. Pinto,et al.  Identification of Tissue Transglutaminase as a Novel Molecule Involved In Human CD8+ T Cell Transendothelial Migration 1 , 2003, The Journal of Immunology.

[25]  Masashi Kikuchi,et al.  A novel function of tissue-type transglutaminase: protein disulphide isomerase. , 2003, The Biochemical journal.

[26]  Yun-ping Zhu,et al.  Identification of metastasis‐associated proteins by proteomic analysis and functional exploration of interleukin‐18 in metastasis , 2003, Proteomics.

[27]  Robert M. Graham,et al.  Transglutaminases: crosslinking enzymes with pleiotropic functions , 2003, Nature Reviews Molecular Cell Biology.

[28]  Mauro Piacentini,et al.  Transglutaminase 2: an enigmatic enzyme with diverse functions. , 2002, Trends in biochemical sciences.

[29]  S. Akimov,et al.  Cell surface tissue transglutaminase is involved in adhesion and migration of monocytic cells on fibronectin. , 2001, Blood.

[30]  S. Akimov,et al.  Tissue Transglutaminase Is an Integrin-Binding Adhesion Coreceptor for Fibronectin , 2000, The Journal of cell biology.

[31]  K. Mehta.  High levels of transglutaminase expression in doxorubicin‐resistant human breast carcinoma cells , 1994, International journal of cancer.

[32]  R. Graham,et al.  Gh: a GTP-binding protein with transglutaminase activity and receptor signaling function. , 1994, Science.

[33]  K. Mehta,et al.  Tissue transglutaminase: from biological glue to cell survival cues. , 2006, Frontiers in bioscience : a journal and virtual library.

[34]  S. Park,et al.  Reduction of transglutaminase 2 expression is associated with an induction of drug sensitivity in the PC-14 human lung cancer cell line , 1999, Journal of Cancer Research and Clinical Oncology.

[35]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.